Androgen receptor (AR) plays a central role in prostate cancer (PCa) development, and androgen deprivation therapy (ADT) to reduce levels of circulating androgens (testosterone and dihydrotestosterone, DHT) is the standard treatment for metastatic PCa. This evidence concerns the gene AR and posterior cortical atrophy.